Drug Discovery Featured Articles & Applications

1. Heart-In-A-Jar Organ Model Earns Regulatory Respect After 25 Years In The Making 8/7/2025

   Aligned with new FDA support for new approach methodologies (NAMs), Ronald Li, Ph.D, and Kevin Costa, Ph.D., share their story of creating Novoheart's mini heart organ model and discuss its current use in clinical trials.

2. Developing Small Molecule Therapeutics To Tackle Heart Failure In DMD Patients 8/6/2025

   A great deal of attention has been focused on development of genetic therapies to treat DMD. But Revidia Therapeutics is focusing on developing small molecule drugs.

3. The Rise Of NAMs 7/31/2025

   New Approach Methods (NAMs) are rapidly being accepted as replacements for preclinical animal tests long considered to be the gold standard. NAMs include systems of organoids, organs-on-chips, AI-based prediction models, and non-mammalian species.

4. AI Data Security: The 83% Compliance Gap Facing Pharmaceutical Companies 7/23/2025

   A new study reveals a shocking truth: only 17% of pharmaceutical companies — including many CDMOs — have implemented automated controls to prevent sensitive data from leaking through AI tools.

5. Breaking Down Silos: How ERP Platforms Are Accelerating Drug Discovery And Early-Stage Development 7/23/2025

   Modern enterprise resource planning (ERP) systems, particularly those built with pharma in mind, can be tailored specifically to support research workflows just as effectively as they manage commercial operations.

6. FDA Leading The Decline Of Animal Testing 7/16/2025

   The gold standard practice of conducting animal studies for evaluating toxicity, pharmacodynamics, and immunogenicity is being challenged by innovative alternatives – New Approach Methods (NAMs).

7. From Discovery To Delivery: Accelerating The Path Forward For Gene Therapies 7/11/2025

   We caught up with Lexeo Therapeutics’ Manny Otero, Ph.D., and Sandi See Tai, MD, to explore strategies to advance gene therapies.

8. The Evolving Landscape Of Drug Discovery Services 7/11/2025

   Pharma and biotech companies are set to pursue partnerships with drug discovery service providers at an increased rate in the years ahead. And it’s not just small and emerging drug companies; it’s also Big Pharma.

9. TYK2 Inhibition Emerges As A Next-Gen Strategy To Treat PsA 7/10/2025

   The treatment landscape for psoriatic arthritis (PsA) is evolving rapidly, with data presented at EULAR 2025 signaling a new chapter in disease management with the emergence of a selective tyrosine kinase 2 (TYK2) inhibitor.

10. Multi-Indication Strategies Reshape Immunology's R&D Strategy 7/10/2025

    A clear trend at EULAR 2025 emerged across presentations and pipelines: leading biopharma players are increasingly embracing multi-indication strategies, designing assets to work across dermatology, rheumatology, and gastroenterology indications.